Since December 2019, a new disease is challenging us in an unprecedented manner. The novel coronavirus SARS-CoV-2 has rapidly spread worldwide and infected at least 5 million individuals in less than five months. We are in the middle of the most serious global health crisis since the emergencence of the epidemic caused by the human immunodeficiency virus in the 1980s. Usually, we manage our patients and give recommendations in an evidence-based way; however, in these novel times, we have little evidence at our disposal. Also, the speed and amount of mainstream and social media sharing information which has not been reviewed in a scientific rigour is challenging us further.

So how do we move forward as clinicians, researchers, and policymakers in the coming months? First of all, we have to integrate our response into the emerging evidence and keep principles of scientific rigour and peer-review at the highest level despite the time pressure. So far, the majority of COVID-19 cases occurred in adults and particularly in older adults so the disease in children has been less well described \[[@CR1]\]. It this therefore important to publish data on large case series from all countries worldwide. We published an Italian series by Parri and co-authors that shows the clinical spectrum of pediatric COVID-19 including severe and critical cases in 15% of the patients \[[@CR2]\]. Importantly, infants less than six months of age seem at increased risk. So while the risk factors from COVID-19 in adults have been well described so far, including obesity, hypertension, and older age \[[@CR3]\], such factors remain to be determined in children \[[@CR4]\].

Further to this, regular, systematic reviews will be required, and the challenge will be to strike the right time to summarise current data. The international database of prospectively registered systematic reviews (PROSPERO) lists as of 26 May 2020 more than 1000 systematic reviews on COVID-19 of which more than 200 included children. Several systematic reviews were published, including in pediatrics \[[@CR1], [@CR5]--[@CR7]\] with still limited numbers of children included. The first systematic review published in the *European Journal of Pediatrics* by Liguora and colleagues includes 62 pediatric studies published by 1 May 2020 including 7480 children and confirms the mild to moderate spectrum of the disease \[[@CR8]\]. Importantly in one fifth of the cases, the children had an underlying illness with lung disease including asthma, congenital heart disease, and hemato-oncological disease being most frequently described.

Finally, it will also be essential to collect data in children in larger national and international registries, as COVID-19 will be too rare in smaller countries and ethnic factors may play a role in the disease severity. A further study selected for publication by the *European Journal of Pediatrics* describes the set-up and aim of one for the currently establishing networks called EPICENTER to gain further insight into this disease \[[@CR9]\]. As a famous proverb phrases it: if you want to go fast, go alone; if you want to go far, go together. Paediatric COVID-19 requires a fast response but also a long-term perspective, and we will be keen to see results from the EPICENTER and other registries being published in the coming months in the *European Journal of Pediatrics*.
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